549 Characterizing double positive T cells in the tumor microenvironment: a tale of promiscuous cell fates
BackgroundCD4 and CD8 T cells are genetically and functionally distinct cell subsets of the adaptive immune system that play pivotal roles in immune surveillance and disease control. During development in the thymus, transcription factors ThPOK and Runx3 regulate the differentiation and maturation o...
Saved in:
| Published in: | Journal for immunotherapy of cancer Vol. 8; no. Suppl 3; pp. A333 - A334 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BMJ Publishing Group LTD
01.11.2020
BMJ Publishing Group |
| Subjects: | |
| ISSN: | 2051-1426 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | BackgroundCD4 and CD8 T cells are genetically and functionally distinct cell subsets of the adaptive immune system that play pivotal roles in immune surveillance and disease control. During development in the thymus, transcription factors ThPOK and Runx3 regulate the differentiation and maturation of these two lineages into single positive T cells that enter the periphery with mutually exclusive expression of either the CD4 or CD8 co-receptor.1–2 Despite our expectation that these two cell fates are fixed, mature CD4+CD8+ double positive (DP) T cells have been described in the context of numerous immunological responses, including cancer, but their molecular and functional properties and therapeutic relevance remain controversial and largely unknown.3–5 MethodsOur lab has identified and characterized a heterogenous DP T cell population in murine and human melanoma tumors comprised of CD4 and CD8 T cells re-expressing the opposite co-receptor and a parallel uptake in the opposite cell type’s phenotype and function. Using CD4 (Trp1) and CD8 (Pmel) transgenic TCR T cells specific to B16 melanoma antigens gp75 and gp100 respectively, we demonstrate the re-expression of the opposite co-receptor following adoptive T cell transfer in B16 melanoma tumor bearing mice.ResultsSpecifically, up to 50% of transferred CD4 Trp1 T cells will re-express CD8 to become a DP T cell in the tumor microenvironment. Further, these CD4 derived DP T cells upregulate CD8 lineage regulator Runx3 and cytolytic genes Gzmb, Gzmk, and Prf1 to become potent cytotoxic T cells. Alternatively, a subset of CD8 Pmel T cells differentiate into DP T cells characterized by the increased expression of CD4, ThPOK, and regulatory marker FoxP3 (figure 1). In addition, we utilized 10x single cell and ATAC sequencing to further characterize these divergent DP T cell populations among open repertoire T cells isolated from murine and human melanoma tumors.ConclusionsOur findings highlight the capability of single positive T cells to differentiate in response to antigen and local stimuli into novel T cell subsets with polyfunctional characteristics. The resulting cell subsets will potentially affect the tumor microenvironment in distinct ways. Our studies may inform therapeutic approaches to identify antigen specific T cells as well as innovative signaling pathways to target when genetically engineering T cells to optimize cytotoxic function in the setting of adoptive cell therapy.Ethics ApprovalThe human biospecimen analyses were approved by Memorial Sloan Kettering Cancer Center IRB #06-107ReferencesEllmeier W, Haust L & Tschismarov R. Transcriptional control of CD4 and CD8 coreceptor expression during T cell development. Cell Mol Life Sci 2013;70:4537–4553.Luckey MA, et al. The transcription factor ThPOK suppresses Runx3 and imposes CD4+ lineage fate by inducing the SOCS suppressors of cytokine signaling. Nature Immunology 2014; 15, 638–645.Bohner P, et al. Double positive CD4(+)CD8(+) T Cells are enriched in urological cancers and favor T Helper-2 polarization. Front Immunol 2019; 10, 622.Nascimbeni M, Shin E-C, Chiriboga L, Kleiner DE & Rehermann B. Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood 2004;104:478–486.Nishida K, et al. Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. Int Immunol 2020;32:347–357. |
|---|---|
| AbstractList | BackgroundCD4 and CD8 T cells are genetically and functionally distinct cell subsets of the adaptive immune system that play pivotal roles in immune surveillance and disease control. During development in the thymus, transcription factors ThPOK and Runx3 regulate the differentiation and maturation of these two lineages into single positive T cells that enter the periphery with mutually exclusive expression of either the CD4 or CD8 co-receptor.1–2 Despite our expectation that these two cell fates are fixed, mature CD4+CD8+ double positive (DP) T cells have been described in the context of numerous immunological responses, including cancer, but their molecular and functional properties and therapeutic relevance remain controversial and largely unknown.3–5MethodsOur lab has identified and characterized a heterogenous DP T cell population in murine and human melanoma tumors comprised of CD4 and CD8 T cells re-expressing the opposite co-receptor and a parallel uptake in the opposite cell type’s phenotype and function. Using CD4 (Trp1) and CD8 (Pmel) transgenic TCR T cells specific to B16 melanoma antigens gp75 and gp100 respectively, we demonstrate the re-expression of the opposite co-receptor following adoptive T cell transfer in B16 melanoma tumor bearing mice.ResultsSpecifically, up to 50% of transferred CD4 Trp1 T cells will re-express CD8 to become a DP T cell in the tumor microenvironment. Further, these CD4 derived DP T cells upregulate CD8 lineage regulator Runx3 and cytolytic genes Gzmb, Gzmk, and Prf1 to become potent cytotoxic T cells. Alternatively, a subset of CD8 Pmel T cells differentiate into DP T cells characterized by the increased expression of CD4, ThPOK, and regulatory marker FoxP3 (figure 1). In addition, we utilized 10x single cell and ATAC sequencing to further characterize these divergent DP T cell populations among open repertoire T cells isolated from murine and human melanoma tumors.ConclusionsOur findings highlight the capability of single positive T cells to differentiate in response to antigen and local stimuli into novel T cell subsets with polyfunctional characteristics. The resulting cell subsets will potentially affect the tumor microenvironment in distinct ways. Our studies may inform therapeutic approaches to identify antigen specific T cells as well as innovative signaling pathways to target when genetically engineering T cells to optimize cytotoxic function in the setting of adoptive cell therapy.Ethics ApprovalThe human biospecimen analyses were approved by Memorial Sloan Kettering Cancer Center IRB #06-107ReferencesEllmeier W, Haust L & Tschismarov R. Transcriptional control of CD4 and CD8 coreceptor expression during T cell development. Cell Mol Life Sci 2013;70:4537–4553.Luckey MA, et al. The transcription factor ThPOK suppresses Runx3 and imposes CD4+ lineage fate by inducing the SOCS suppressors of cytokine signaling. Nature Immunology 2014; 15, 638–645.Bohner P, et al. Double positive CD4(+)CD8(+) T Cells are enriched in urological cancers and favor T Helper-2 polarization. Front Immunol 2019; 10, 622.Nascimbeni M, Shin E-C, Chiriboga L, Kleiner DE & Rehermann B. Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood 2004;104:478–486.Nishida K, et al. Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. Int Immunol 2020;32:347–357. BackgroundCD4 and CD8 T cells are genetically and functionally distinct cell subsets of the adaptive immune system that play pivotal roles in immune surveillance and disease control. During development in the thymus, transcription factors ThPOK and Runx3 regulate the differentiation and maturation of these two lineages into single positive T cells that enter the periphery with mutually exclusive expression of either the CD4 or CD8 co-receptor.1–2 Despite our expectation that these two cell fates are fixed, mature CD4+CD8+ double positive (DP) T cells have been described in the context of numerous immunological responses, including cancer, but their molecular and functional properties and therapeutic relevance remain controversial and largely unknown.3–5 MethodsOur lab has identified and characterized a heterogenous DP T cell population in murine and human melanoma tumors comprised of CD4 and CD8 T cells re-expressing the opposite co-receptor and a parallel uptake in the opposite cell type’s phenotype and function. Using CD4 (Trp1) and CD8 (Pmel) transgenic TCR T cells specific to B16 melanoma antigens gp75 and gp100 respectively, we demonstrate the re-expression of the opposite co-receptor following adoptive T cell transfer in B16 melanoma tumor bearing mice.ResultsSpecifically, up to 50% of transferred CD4 Trp1 T cells will re-express CD8 to become a DP T cell in the tumor microenvironment. Further, these CD4 derived DP T cells upregulate CD8 lineage regulator Runx3 and cytolytic genes Gzmb, Gzmk, and Prf1 to become potent cytotoxic T cells. Alternatively, a subset of CD8 Pmel T cells differentiate into DP T cells characterized by the increased expression of CD4, ThPOK, and regulatory marker FoxP3 (figure 1). In addition, we utilized 10x single cell and ATAC sequencing to further characterize these divergent DP T cell populations among open repertoire T cells isolated from murine and human melanoma tumors.ConclusionsOur findings highlight the capability of single positive T cells to differentiate in response to antigen and local stimuli into novel T cell subsets with polyfunctional characteristics. The resulting cell subsets will potentially affect the tumor microenvironment in distinct ways. Our studies may inform therapeutic approaches to identify antigen specific T cells as well as innovative signaling pathways to target when genetically engineering T cells to optimize cytotoxic function in the setting of adoptive cell therapy.Ethics ApprovalThe human biospecimen analyses were approved by Memorial Sloan Kettering Cancer Center IRB #06-107ReferencesEllmeier W, Haust L & Tschismarov R. Transcriptional control of CD4 and CD8 coreceptor expression during T cell development. Cell Mol Life Sci 2013;70:4537–4553.Luckey MA, et al. The transcription factor ThPOK suppresses Runx3 and imposes CD4+ lineage fate by inducing the SOCS suppressors of cytokine signaling. Nature Immunology 2014; 15, 638–645.Bohner P, et al. Double positive CD4(+)CD8(+) T Cells are enriched in urological cancers and favor T Helper-2 polarization. Front Immunol 2019; 10, 622.Nascimbeni M, Shin E-C, Chiriboga L, Kleiner DE & Rehermann B. Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood 2004;104:478–486.Nishida K, et al. Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. Int Immunol 2020;32:347–357. |
| Author | Mangarin, Levi Hirschhorn-Cymerman, Daniel Zhong, Hong Zappasodi, Roberta Merghoub, Taha Wolchok, Jedd Budhu, Sadna Yang, Xia Elemento, Olivier Gigoux, Mathieu Schad, Sara Redmond, David Pan, Heng Chow, Andrew |
| Author_xml | – sequence: 1 givenname: Sara surname: Schad fullname: Schad, Sara organization: WCMC, New York, NY, USA – sequence: 2 givenname: Andrew surname: Chow fullname: Chow, Andrew organization: WCMC, New York, NY, USA – sequence: 3 givenname: Heng surname: Pan fullname: Pan, Heng organization: WCMC, New York, NY, USA – sequence: 4 givenname: Levi surname: Mangarin fullname: Mangarin, Levi organization: WCMC, New York, NY, USA – sequence: 5 givenname: Roberta surname: Zappasodi fullname: Zappasodi, Roberta organization: WCMC, New York, NY, USA – sequence: 6 givenname: Mathieu surname: Gigoux fullname: Gigoux, Mathieu organization: WCMC, New York, NY, USA – sequence: 7 givenname: David surname: Redmond fullname: Redmond, David organization: WCMC, New York, NY, USA – sequence: 8 givenname: Daniel surname: Hirschhorn-Cymerman fullname: Hirschhorn-Cymerman, Daniel organization: WCMC, New York, NY, USA – sequence: 9 givenname: Sadna surname: Budhu fullname: Budhu, Sadna organization: WCMC, New York, NY, USA – sequence: 10 givenname: Hong surname: Zhong fullname: Zhong, Hong organization: WCMC, New York, NY, USA – sequence: 11 givenname: Xia surname: Yang fullname: Yang, Xia organization: WCMC, New York, NY, USA – sequence: 12 givenname: Olivier surname: Elemento fullname: Elemento, Olivier organization: WCMC, New York, NY, USA – sequence: 13 givenname: Jedd surname: Wolchok fullname: Wolchok, Jedd organization: WCMC, New York, NY, USA – sequence: 14 givenname: Taha surname: Merghoub fullname: Merghoub, Taha organization: WCMC, New York, NY, USA |
| BookMark | eNpFkc1u1TAQhS0EEqX0GbDEOmVsx47DDl3xc6VKLHpZW_6ZtL5K4ovtVIJVN7woT0LSC2I1o9E5Z2b0vSLP5zQjIW8YXDMm1LtjrL7hwKG53R92W3MNsu2fkQsOkjWs5eoluSrlCAAMhNBaX5BxVfx-_LW7t9n6ijn-jPMdDWlxI9JTKrHGB6QH6nEcC40zrfdI6zKlTKfoc8L5IeY0TzjX99TSaldbGugppykWv6SlPFnpYCuW1-TFYMeCV3_rJfn26eNh96W5-fp5v_tw0zimVd8MXEiFiBZbDdB2zocuSN9zVChbwCCC7HoXsBOugzAo11k-KFBMKoe-FZdkf84NyR7NKcfJ5h8m2WieBinfGZtr9COawLm2QeCgFLR64BaD7XqJqmXWgbZr1ttz1vrS9wVLNce05Hk933Aped_rde-q4meVm_4vZGA2MGYDYzYe5h8Ys4ERfwAhuYgZ |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. 2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. – notice: 2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 9YT ACMMV 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS DOA |
| DOI | 10.1136/jitc-2020-SITC2020.0549 |
| DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China DOAJ Directory of Open Access Journals |
| DatabaseTitle | Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) |
| DatabaseTitleList | Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2051-1426 |
| EndPage | A334 |
| ExternalDocumentID | oai_doaj_org_article_d228ad3ef66048f2aeda795e641ab08a jitc |
| GroupedDBID | 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV ADRAZ ADUKV AFKRA AHBYD AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E OK1 PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RMJ ROL RPM RSV SOJ UKHRP 3V. 7XB 8FK AZQEC DWQXO K9. PHGZM PJZUB PKEHL PPXIY PQEST PQUKI PRINS |
| ID | FETCH-LOGICAL-b1869-f2356eeeae480047bcd7d5c92e6e540ed3d579bde73b70df6b7a2f606156bec43 |
| IEDL.DBID | BENPR |
| IngestDate | Fri Oct 03 12:45:47 EDT 2025 Tue Oct 07 06:43:16 EDT 2025 Thu Apr 24 22:50:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Suppl 3 |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b1869-f2356eeeae480047bcd7d5c92e6e540ed3d579bde73b70df6b7a2f606156bec43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| OpenAccessLink | https://www.proquest.com/docview/2552998061?pq-origsite=%requestingapplication% |
| PQID | 2552998061 |
| PQPubID | 2040222 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d228ad3ef66048f2aeda795e641ab08a proquest_journals_2552998061 bmj_primary_10_1136_jitc_2020_SITC2020_0549 |
| PublicationCentury | 2000 |
| PublicationDate | 20201100 20201101 2020-11-01 |
| PublicationDateYYYYMMDD | 2020-11-01 |
| PublicationDate_xml | – month: 11 year: 2020 text: 20201100 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | Journal for immunotherapy of cancer |
| PublicationYear | 2020 |
| Publisher | BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| SSID | ssj0001033888 |
| Score | 2.1230707 |
| Snippet | BackgroundCD4 and CD8 T cells are genetically and functionally distinct cell subsets of the adaptive immune system that play pivotal roles in immune... |
| SourceID | doaj proquest bmj |
| SourceType | Open Website Aggregation Database Publisher |
| StartPage | A333 |
| SubjectTerms | Antigens Antiviral drugs Cytotoxicity Immunotherapy Kidney cancer Lymphocytes Melanoma Tumors Urological cancer |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV09T8MwELUAIcSC-BSFgjywoUAaJ7bDBhUVDCAkisRmxfZZakUb1DYdmFj4o_wSzk5AlRhY2KIoH857l9w753xHyAlGDLnVSRZpq3WUGsMjmRoZOQGCGTSRmJnQbELc38vn5_xhodWXzwmrywPXwJ3bJJGFZeA4R2NzSQG2EHkGPO0UOpZBGqHqWQimwuxKjKGXlE1CV4fx8-FgZtAkMFh6vO13_cYZqhUUlst6NGwK9v_6Hgcn09skG406pJf1qLbIEoy3ydpd8_97h7zgtT7fP7o_VZbf0PNQW1b6BWidfzUH2qd-On5KB2OK8o7OqlE5oSOfebewrO2CFhSFN9DSURwO0m2qspqGU6nzCnSXPPWu-92bqOmXEGnfWCpyCcs4ABSQSl8FUhsrbGbyBDigMAPLbCZybZEFLWLruBZF4rgXNRypTNkeWRmXY9gnNLMmNs4YxxKbcshz07HCCEBXhi951mmRU4RNvdYVMVSIJBhXHmTlsVXfICsPcotceXh_DvclrcMOJFo1RKu_iG6R9jc5qnnPpgrHgv5U4iMc_Mc9Dsl6MJGw1rBNVmaTCo7IqpnPBtPJcTCxL0HG11o priority: 102 providerName: Directory of Open Access Journals |
| Title | 549 Characterizing double positive T cells in the tumor microenvironment: a tale of promiscuous cell fates |
| URI | https://jitc.bmj.com/content/8/Suppl_3/A333.2.full https://www.proquest.com/docview/2552998061 https://doaj.org/article/d228ad3ef66048f2aeda795e641ab08a |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free databaseCode: RBZ dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.biomedcentral.com/search/ omitProxy: false ssIdentifier: ssj0001033888 providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals databaseCode: DOA dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.doaj.org/ omitProxy: false ssIdentifier: ssj0001033888 providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources databaseCode: M~E dateStart: 20130101 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://road.issn.org omitProxy: false ssIdentifier: ssj0001033888 providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection databaseCode: 7X7 dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://search.proquest.com/healthcomplete omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central databaseCode: BENPR dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: https://www.proquest.com/central omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database databaseCode: PIMPY dateStart: 20130501 customDbUrl: isFulltext: true eissn: 2051-1426 dateEnd: 99991231 titleUrlDefault: http://search.proquest.com/publiccontent omitProxy: false ssIdentifier: ssj0001033888 providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB6RFCEuvBGBEvnADS3d7MP2ckE0akUPjSIIUjhZa3uMUjXZNpvtoScu_FF-CWPHaZGQuHDbp2T5G898Mx7PALwhj6GyOisTbbVOCmN4IgsjEydQ5IZEJM1NaDYhJhM5n1fTGHBrY1rlTicGRW0b42PkB0R9SXNKMj8fLi4T3zXK767GFho92POVyoo-7B0eTaafb6MsKblgUsbErlHOD84WG0OiQU7Tl5PZ2F-8I9ZCBLOnl2excP9fejkYm-OH_zvMR_Ag0kz2cSsXj-EOrp7AvdO4kf4Uzmkwv378HN-Ua74mE8Zs0-lzZNtEritkM-bj-i1brBjxRLbpls2aLX0K3x_n496zmhGDR9Y4RoMluTFd07XhV-Y8lX0GX4-PZuNPSWy8kGjfoSpxWV5yRKyxkL6cpDZW2NJUGXIkhoc2t6WotCU4tUit41rUmeOeHXGSiSJ_Dv1Vs8IXwEprUuOMcXlmC45VZUZWGIFkE0lblKMBvKV5Vxfb0hoquCQ5Vx4l5cFRO5SUR2kAhx6fm899bezwoFl_V3GpKZtlsrY5Os5JPbmsRluLqkRejGqdynoA-zvoVFywrbrF7eW_X7-C-0F6wnHEfehv1h2-hrvmarNo10PoibkYRikcBgef7qYnp9NvvwF7KOmN |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1Z3Nb9MwFMCftg7BLnyjFQb4ACcUljqJnSAhBIVp1daqEkUaJy-2n1GntRlNMwQnLvw7_FH8JTynyYaExG0HblG-FNu_vA_7-T2AJ-QxZFbzJNBW6yA2RgRpbNLASZSRIUTCyNTFJuRolB4eZuM1-NnuhfFhla1MrAW1LYyfI98h05ckZ0rq59Xp58BXjfKrq20JjRUW-_j1C7ls5cvBWxrfp5zvvpv094KmqkCgffmlwPEoEYiYY5z6XInaWGkTk3EUSOYL2sgmMtOWvlXL0DqhZc6d8KpfUIPjiN67DhsxwZ52YGM8GI4_XszqhOTypWkTSNaLxM7xdGkIRXLS3g8mfX_wnKwkMmjX9ey4KRTwlx6oldvujf-tW27C9caMZq9X3N-CNZzfhqvDJlDgDpxQ4399_9E_T0f9jVQ0s0WlT5CtAtXOkE2YX7co2XTOyA5my2pWLNjMhyj-sf_vBcsZeSjICseoc-i_MFVRlfWjzHlT_S58uJS23oPOvJjjFrDEmtA4Y1zEbSwwy0zPSiORdD4BkvS68IzGWZ2uUoeo2uWKhPJUKA-DaqlQnoouvPE8nN_uc3_XJ4rFJ9WIEmU5T3MboROCxK_jOdpcZgmKuJfrMM27sN2iohqBVKoLTu7_-_JjuLY3GR6og8Fo_wFs1uTWWy-3obNcVPgQrpiz5bRcPGrYZ3B02Vz9BrHERIo |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB71B1VcKL9ioYAPcEJhs05iJ0gVgi0rVqWrlVikcjKxPUZbdTdlsymip154KR6HJ2GcTVokJG49cIsSJ4rtb2a-scczAE_JY8is5kmgrdZBbIwI0tikgZMoI0MQCSNTF5uQo1F6eJiN1-BnexbGh1W2OrFW1LYwfo28S9SXNGdK5qfrmrCI8d7g1cnXwFeQ8jutbTmNFUT28fs3ct_K3eEezfUzzgdvJ_13QVNhINC-FFPgeJQIRMwxTn3eRG2stInJOAokKoM2sonMtKX_1jK0TmiZcyc8DRDU-Tii767DJlHymGRsczw8GH-6XOEJyf1L0yaorBeJ7tF0aQiW5LB9GE76_uIFMSYit-t6dtQUDfjLJtSGbrD9Pw_RTbjR0Gv2eiUPt2AN57dh66AJILgDxzQQv85_9C_SVJ-R6Wa2qPQxslUA2ymyCfP7GSWbzhnxY7asZsWCzXzo4h_nAl-ynJHngqxwjAaK5MVURVXWrzLnKfxd-Hglfb0HG_NijveBJdaExhnjIm5jgVlmelYaicQFSEsmvQ48pzlXJ6uUIqp2xSKhPEKUB4ZqEaI8QjrwxmPjornPCV7fKBZfVKNilOU8zW2ETghSy47naHOZJSjiXq7DNO_ATgsb1SiqUl1i5sG_Hz-BLQKTej8c7T-E6zWI6xOZO7CxXFT4CK6Z0-W0XDxuxIDB56uG1W_6rU1K |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=549%E2%80%85Characterizing+double+positive+T+cells+in+the+tumor+microenvironment%3A+a+tale+of+promiscuous+cell+fates&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Schad%2C+Sara&rft.au=Chow%2C+Andrew&rft.au=Pan%2C+Heng&rft.au=Mangarin%2C+Levi&rft.date=2020-11-01&rft.eissn=2051-1426&rft.volume=8&rft.issue=Suppl+3&rft.spage=A333&rft.epage=A334&rft_id=info:doi/10.1136%2Fjitc-2020-SITC2020.0549&rft.externalDBID=40425&rft.externalDocID=jitc |